X0202 SCHEDULE 13G/A 0001955231 XXXXXXXX LIVE 6 Common Stock, par value $0.005 per share 02/10/2026 0000748592 Ernexa Therapeutics Inc. 114082407 1035 Cambridge Street Suite 18A Cambridge MA 02141 Rule 13d-1(c) Freebird Partners LP b TX 0 120412 0 120412 120412 N 9.9 PN Freebird Investments LLC, a Texas limited liability company ("Freebird Investments"), serves as the general partner of Freebird Partners LP, a Texas limited partnership ("Freebird Partners"). Curtis W. Huff is the sole member of Freebird Investments. By virtue of these relationships, each of Freebird Investments and Mr. Huff may be deemed to share beneficial ownership of the securities held of record by Freebird Partners. The number of shares of Common Stock owned by the Reporting Person reflects Ernexa Therapeutics Inc.'s (the "Issuer") 1-for-25 reverse stock split of its outstanding shares of common stock, par value $0.005 per share (the "Common Stock") that was effected on May 4, 2026 (the "Reverse Stock Split"), as reported. Rows 6, 8 and 9 are based on (i) 81,417 shares of Common Stock of the Issuer, (ii) 52,000 shares of Common Stock issuable upon the exercise of warrants to purchase 52,000 shares of Common Stock at an exercise price of $17.00 (the "Common Warrants"), and (iii) 15,015 shares of Common Stock issuable upon the exercise of pre-funded warrants to purchase 15,015 shares of Common Stock at an exercise price of $1.875 per share (the "Pre-funded Warrants" and together with the Common Warrants, the "Warrants"). Pursuant to the terms of the Warrants, the Reporting Person cannot exercise the Warrants to the extent the Reporting Person would beneficially own, after any such exercise, more than 9.99% of the outstanding shares of Common Stock. As a result, Rows 6, 8 and 9 exclude 28,020 shares of Common Stock issuable upon exercise of the Warrants because of this limitation. Row 11 is calculated based on an aggregate of 1,205,328 shares of Common Stock of the Issuer outstanding, which is calculated by adding (i) 1,166,333 shares of Common Stock of the Issuer outstanding as of May 8, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 11, 2026, and (ii) 38,995 shares of Common Stock of the Issuer issuable to the Reporting Person upon exercise of the Warrants within 60 days, and which, for (ii), is deemed outstanding pursuant to Rule 13d-3(d)(1)(i). This Amendment No. 6 to Schedule 13G amends the Schedule 13G filed by the Reporting Persons named therein on December 2, 2022, as amended and supplemented to date. Freebird Investments LLC b TX 0 120412 0 120412 120412 N 9.9 OO As noted above, Freebird Investments serves as the general partner of Freebird Partners and, as a result, may be deemed to share beneficial ownership of the securities held of record by Freebird Partners. The number of shares of Common Stock owned by the Reporting Person reflects the Reverse Stock Split, as reported. Rows 6, 8 and 9 are based on (i) 81,417 shares of Common Stock of the Issuer, (ii) 52,000 shares of Common Stock issuable upon the exercise of the Common Warrants, and (iii) 15,015 shares of Common Stock issuable upon the exercise of the Pre-funded Warrants. Pursuant to the terms of the Warrants, the Reporting Person cannot exercise the Warrants to the extent the Reporting Person would beneficially own, after any such exercise, more than 9.99% of the outstanding shares of Common Stock. As a result, Rows 6, 8 and 9 exclude 28,020 shares of Common Stock issuable upon exercise of the Warrants because of this limitation. Row 11 is calculated based on an aggregate of 1,205,328 shares of Common Stock of the Issuer outstanding, which is calculated by adding (i) 1,166,333 shares of Common Stock of the Issuer outstanding as of May 8, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 11, 2026, and (ii) 38,995 shares of Common Stock of the Issuer issuable to the Reporting Person upon exercise of the Warrants within 60 days, and which, for (ii), is deemed outstanding pursuant to Rule 13d-3(d)(1)(i). Curtis Huff b X1 0 120412 0 120412 120412 N 9.9 IN As noted above, Curtis W. Huff is the sole member of Freebird Investments, which is the general partner of Freebird Partners, and, as a result, he may be deemed to share beneficial ownership of the securities held of record by Freebird Partners. The number of shares of Common Stock owned by the Reporting Person reflects the Reverse Stock Split, as reported. Rows 6, 8 and 9 consist of (i) 81,417 shares of Common Stock of the Issuer, (ii) 52,000 shares of Common Stock issuable upon the exercise of the Common Warrants, and (iii) 15,015 shares of Common Stock issuable upon the exercise of Pre-funded Warrants. Pursuant to the terms of the Warrants, the Reporting Person cannot exercise the Warrants to the extent the Reporting Person would beneficially own, after any such exercise, more than 9.99% of the outstanding shares of Common Stock. As a result, Rows 6, 8 and 9 exclude 28,020 shares of Common Stock issuable upon exercise of the Warrants because of this limitation. Row 11 is calculated based on an aggregate of 1,205,328 shares of Common Stock of the Issuer outstanding, which is calculated by adding (i) 1,166,333 shares of Common Stock of the Issuer outstanding as of May 8, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 11, 2026, and (ii) 38,995 shares of Common Stock of the Issuer issuable to the Reporting Person upon exercise of the Warrants within 60 days, and which, for (ii), is deemed outstanding pursuant to Rule 13d-3(d)(1)(i). Ernexa Therapeutics Inc. 1035 Cambridge Street, Suite 18A, Cambridge, MA 02141 This statement is filed by the following entities and individuals (collectively, referred to as the "Reporting Persons"): *Freebird Partners LP, a Texas limited partnership; *Freebird Investments LLC, a Texas limited liability company; *Curtis W. Huff, an individual and a citizen of the United States of America. Freebird Investments LLC is the general partner of Freebird Partners LP, and as a result, may be deemed to share voting and dispositive power with respect to the securities held by Freebird Partners LP. Curtis Huff is the sole member of Freebird Investments LLC, which is the general partner of Freebird Partners LP, and as a result, may be deemed to share voting and dispositive power with respect to the securities held by Freebird Partners LP. Freebird Partners LP, Freebird Investments LLC, and Mr. Huff have entered into a Joint Filing Agreement, a copy of which was filed with the Schedule 13G on December 2, 2022 as Exhibit 99.1, which is hereby incorporated by reference, pursuant to which they have agreed to file this Amendment No. 6 jointly in accordance with the provisions of Rule 13d-1(k) of the Act. The address of the principal business office for each of the Reporting Person is: 2800 Post Oak Blvd, Suite 2000 Houston, Texas 77056 See Row 4 of each Reporting Person's cover page to this Schedule 13G. Y See Row 9 of each Reporting Person's cover page to this Schedule 13G. See Row 11 of each Reporting Person's cover page to this Schedule 13G. See Row 5 of each Reporting Person's cover page to this Schedule 13G. See Row 6 of each Reporting Person's cover page to this Schedule 13G. See Row 7 of each Reporting Person's cover page to this Schedule 13G. See Row 8 of each Reporting Person's cover page to this Schedule 13G. Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Freebird Partners LP /s/ Curtis Huff 05/15/2026 Freebird Investments LLC /s/ Curtis Huff 05/15/2026 Curtis Huff /s/ Curtis Huff 05/15/2026